CERA

Close Menu

Donate

Donate to CERA

Subscribe

Get monthly updates

Clinical trials

Take part in research
Close Close
Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now

Annual Review 2024

Share our vision
Read or listen to CERA's 2024 Annual Review, which recognises the scientists, supporters, research partners, funders and people with vision loss who all play in role in helping us develop new ways to detect and treat eye diseases, prevent blindness and restore sight.  

Strategy

Impact through innovation: CERA Strategy 2025-2030
Our mission is to lead the way in transforming the future of eye health and vision. Read, download or listen to our roadmap for the next five years.

Consumer involvement

Help shape the future of vision research
Our new Consumer Program is working alongside people with lived experience to ensure their insights are at the heart of advancing eye research. Learn about the program and meet our Consumer Advisory Group.

Cerulea Clinical Trials

Cerulea Clinical Trials, CERA’s new not-for-profit clinical trials centre, is up and running.
Learn how Cerulea is transforming the delivery of ophthalmic clinical trials, increasing community access to sight-saving therapies and delivering excellence for clinicians, trial participants and sponsors.

Read more

Take part in research

Help shape the future of vision research by taking part in a clinical study.
Find out how you can take part in studies at CERA and Cerulea Clinical Trials for eye conditions including age-related macular degeneration, corneal conditions, diabetic retinopathy, glaucoma and inherited retinal disease.

Learn more

Latest News
News

New recruits boost glaucoma and inherited retinal disease research

21 August 2025

The Centre for Eye Research Australia has announced key scientific appointments to boost its glaucoma and inherited retinal disease research programs in 2026.
News

Investment advances cell reprogramming research

14 August 2025

Cell reprogramming spin-out company Mirugen has secured up to $AUD 4.5M in seed funding from a consortium of investors to advance research into a treatment for the incurable genetic eye disease retinitis pigmentosa.
News

World-first glimpse at cataract genetics

11 June 2025

A new CERA study has looked at the genes associated with different types of cataracts in a first step towards targeted therapies and perhaps even ways to prevent cataracts altogether.
Videos

2025 Gerard Crock Lecture: Professor Robyn Guymer AM

11 June 2025

Watch Professor Robyn Guymer AM present the 16th Gerard Crock Lecture: “How will we know when we are there? How to prove a treatment for macular degeneration is actually effective.”

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.